2008: RA: Assessment of Disease Activity and Outcomes

RA: Assessment of Disease Activity and Outcomes

Tuesday, October 28, 2008

1590

Development of a novel DNA Microarray Chip to predict functional impairment and remission in Rheumatoid Arthritis

1591

Ultrasonography in the assessment of remission in Rheumatoid Arthritis

1592

Differences in Inflammatory Arthritis Disease Severity Among Mexican Mestizos and Native American Indians Compared to Caucasians

1593

Measurement of Baseline Serum Matrix Metalloproteinase Levels Adds Minimal Prognostic Value Over Routine Clinical Parameters in the Prediction of Radiographic Erosions in Early Inflammatory Arthritis

1594

The Improving 5-year Mortality Risk for Individuals with Rheumatoid Factor Positive Polyarthritis

1595

Disconnect between Clinical Disease Activity and X-ray Damage In Early Rheumatoid Arthritis

1596

Matrix Risk Model for Prediction of Rapid Radiographic Progression in Rheumatoid Arthritis

1597

Prediction of Patient Satisfaction with Treatment in RA Using Different Techniques to Assess Disease Activity: Insights from the Abatacept Database in Inadequate Responders to Anti-TNF Therapy

1598

Patient-Reported Swollen and Tender 28-Joint Counts Accurately Represent RA Disease Activity and Can Be Used To Calculate DAS28 on a Group Level

1599

Development of a Web-based Screening Tool for Early Rheumatoid Arthritis-ERASE: the E-triage RA Study in Early Arthritis

1600

The Burden of Medical Expenses Does Not Fall Equally on All with RA: Increased Burden for the Poor and Disabled

1601

Can Treatments or the Outcome of RA be Successful if the Patient Doesn’t Think So? Patient Requirements for Successful Outcomes

1602

Gender Differences In The Presentation Of Complaints May Affect The Disease Activity Score (DAS28)

1603

Predicting RA in CCP negative patients: Power Doppler Ultrasound as a surrogate for auto-antibodies in very early inflammatory arthritis

1604

Discrepancies in Rheumatoid Arthritis Response Measures In Clinical Practice: Comparison of Difference in EULAR, ACR20, and Real Time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA)

1605

An Algorithm Including The Intrasynovial Expression Of CD20 And Serum Biomarkers (rheumatoid Factors, Anti-CCP2 And RANK-ligand) Able To Predict The Progression Of Bone Erosions In Very Early Arthritis

1606

Comparison between Sharp/van der Heijde (SHS) Method and Simple Erosion Narrowing Score (SENS) Method for the Assessment of Radiological Damage in Rheumatoid Arthritis

1607

Healthy Weight: a Major Prognostic Factor for Remission in Early Rheumatoid Arthritis in Daily Clinical Practice

1608

Prevalence and Predictive Factors for DMARD-free Remission in RA: Lessons from two large Early Arthritis Cohorts

1609

Early Rheumatoid Arthritis (ERA) Trials have almost no Generalizability to ERA patients: Results from a Large Multi-center Cohort

1610

Duration of Morning Stiffness in the Assessment of Rheumatoid Arthritis Activity: A Questionable Issue

1611

Increases in Hemoglobin Levels are Associated with Improved Activities of Daily Living (mHAQ) in Rheumatoid Arthritis Patients

1612

Disease Outcomes in Response to Treatment among Patients with Early Rheumatoid Arthritis are not Associated with Gender

1613

Severe Rheumatoid Arthritis Phenotype in Native American Indians Compared to Caucasians

1614

Autoantibody Status in U.S.Veterans with Rheumatoid Arthritis (RA): Implications of Discordance between Anti-CCP Antibody and Rheumatoid Factor

1615

Does Vitamin D Level Influence Limitations in Physical Functioning in Rheumatoid Arthritis?

1616

Anti-Cyclic Citrullinated Peptide Antibody Titer at the First Visit is Correlated with the Next 2 Years' Disease Activity in Patients with Early Rheumatoid Arthritis

1617

How do Elderly Males with Rheumatoid Arthritis Patients View Their Quality of Life?

1618

Fit for Study: Eligibility of Veterans with Rheumatoid Arthritis in Major Clinical Trials of Biological Therapies

1619

Early Good Response to Therapy in RA Patients Predicts a Better Long-term Clinical Course and Less Radiographic Joint Damage

1620

Influence of Age on the Outcome of Anti-TNFα Therapy in Rheumatoid Arthritis

1621

An Audit of the Clinical Care of Patients with Newly Diagnosed Rheumatoid Arthritis In Scotland

1622

Evaluation Of The Two-Examiner Reliability Of The Standard 28-Count Joint Examination In Rheumatoid Arthritis (RA) And Juvenile Idiopathic Arthritis (JIA)

1623

Self-report vs. Assessor Joint Counts in Rheumatoid Arthritis: A Systematic Review

1624

Gender Predicts Remission at One-year in Initial Early Optimal DMARD Therapy in Patients with New Onset Inflammatory Arthritis

1625

Prediction of the Physical Disability Trajectory in Rheumatoid Arthritis

1626

Lymphocyte Organisation and Lymphatic Angiogenesis in Rheumatoid Synovitis: Clinical and Radiographic Correlates

1627

Remission and Rheumatoid Arthritis. Data from 24 Countries in the QUEST-RA Study

1628

Increased Osteoclastogenesis in Patients with Rheumatoid Arthritis

1629

99mTc-albumin nanocolloid Joint Scintigraphy In RA Patients in Clinical Remission

1630

Anti-MCV Antibody Test for the Diagnosis of Rheumatoid Arthritis Using a POCT-Immunoassay

1631

Predictors Of Poor Prognosis In Very Early Inflammatory Polyarthritis

1632

Determining A Low Disease Activity Threshold For Decision To Maintain Dmard Treatment Unchanged In Ra Patients

1633

High Anti-cyclic Citrullinated Peptide Level Is A Stronger Predictor Than Low Level For Persistent Joint Swelling In Patients Presenting With Arthritis Of ≤16 Weeks Duration

1634

Antibodies to Chimeric Citrullinated Synthetic Peptides Derived from Human Fibrin and Filaggrin in Rheumatoid Arthritis: Prognostic Value in Patients with Recent Onset Disease

1635

Diagnostic Value of Antibodies To Chimeric Citrullinated Synthetic Peptides Derived From Human Fibrin And Filaggrin In Rheumatoid Arthritis: A Comparative Study With The CCP-2 Commercial Test

1636

Test-Retest Reliability of ACR Core Data Set Measures and Indices derived from these Measures (DAS28, CDAI, SDAI, RAPID3)

1637

Rheumatoid Arthritis Quality of Care at the Alaska Native Medical Center, 2000-2005

1638

Correlation Between C- Reactive Protein and Disease Activity Indices in Rheumatoid Arthritis

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>